The proposed IL-6-ERRγ-BMP6 pathway is probably active in inflammatory conditions when pro-inflammatory cytokines, including IL-6, levels are increased and may up-regulate hepcidin expression, leading to hypoferremia and anemia, such as in inflammatory anemia. This evidence concerns the gene HAMP and anemia (phenotype).